Sanofi Announces Acquisition of Dynavax for $2.2 Billion
The French pharmaceutical group has signed an agreement to acquire the American company Dynavax Technologies Corporation, specialized in vaccines, according to a press release published this Tuesday. The deal covers all outstanding shares of the listed company, valued at $15.50 per share.
Enhancing Sanofi's Vaccine Portfolio
The acquisition allows Sanofi to integrate HEPLISAV B, a hepatitis B vaccine for adults currently marketed in the United States, the company indicates. This product is distinguished by a two-dose administration schedule over one month, compared to the three doses spread over six months for other available vaccines against this disease. The portfolio also includes a vaccine candidate against shingles, currently in phase 1/2 of clinical development, as well as other ongoing vaccine projects, the group specifies. According to the press release, nearly 100 million adults born before 1991 in the United States are not vaccinated against hepatitis B and present potential risks of infection. Chronic infection with this virus can lead to liver damage, cirrhosis, and liver cancer. Regarding shingles, the World Health Organization indicates that it affects one in three adults during their lifetime, usually causing a painful skin rash but can also lead to more serious complications such as persistent nerve pain or eye infections.
Terms of the Agreement
According to the terms of the agreement, Sanofi launches a cash tender offer for all outstanding shares of Dynavax at $15.50 per share, representing a total valuation of approximately $2.2 billion, the press release specifies. The transaction has received unanimous approval from Dynavax's board of directors. The completion of the operation remains subject to customary conditions, including the tender of a number of shares representing at least the majority of the ordinary shares outstanding, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as well as certain foreign regulatory approvals. The group indicates that it will finance the acquisition through available cash resources. The operation is not expected to affect Sanofi's financial outlook for 2025, according to the company. If all conditions are met, the closure of the acquisition is expected in the first quarter of 2026.
Strategic Implications of the Acquisition
According to Thomas Triomphe, Executive Vice President Vaccines at Sanofi, quoted in the press release, Dynavax brings differentiated vaccines that complement the French group's expertise in adult vaccination. The marketed vaccine against hepatitis B and the vaccine candidate against shingles add new options to the portfolio and underline the group's commitment to providing vaccine protection throughout life, according to his statements. Ryan Spencer, CEO of Dynavax, also quoted, believes that joining Sanofi will bring the global scale and expertise needed to maximize the impact of his company's vaccine portfolio. According to him, Sanofi's commercial presence, development skills, and vision of immunization based on scientific data will amplify the opportunities for HEPLISAV-B and the company's innovative pipeline. He considers that this transaction serves the best interests of the company and its shareholders.
